Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Deadline in Lawsuit for Investors in Insys Therapeutics Inc (NASDAQ:INSY) Announced by Shareholders Foundation
Globe Newswire

SAN DIEGO, Feb. 10, 2016 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Arizona on behalf of certain purchasers of shares of Insys Therapeutics Inc (NASDAQ:INSY) over alleged Securities Laws Violations by Insys Therapeutics.

Investors who purchased shares of Insys Therapeutics Inc (NASDAQ:INSY) have certain options and for certain investors are short and strict deadlines running. Deadline: April 4, 2016. NASDAQ:INSY investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The plaintiff claims that the defendants are alleged to have failed to disclose that the Company was engaged in the illegal and improper off-labeling marketing of Subsys, that certain Insys employees were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys, and that as a result, the Company's financial statements were materially false and misleading at all relevant times.

On April 24, 2015, an article was published entitled "Insys Therapeutics and the New 'Killing It,'" reporting on patients who either died or suffered adverse events while being treated with Subsys. The article also detailed how Insys Therapeutics Inc aggressively markets Subsys.

On May 20, 2015, another article was published entitled "Top prescribers of Insys Therapeutics' Subsys arrested on drug charges," reporting that two of Insys's highest-volume prescribers had been charged with illegal prescription drug distribution by the Drug Enforcement Agency ("DEA"). 

On June 25, 2015, another article reported that a nurse in Connecticut pled guilty to participating in a kickback scheme wherein she accepted approximately $83,000 in kickbacks from Insys Therapeutics Inc in exchange for writing more than $1 million worth of Subsys prescriptions.

On December 3, 2015, another article was published entitled "Murder Incorporated: Insys Therapeutics, Part I," alleging that one Defendant had been forced to resign from the Company by Insys Therapeutics’ founder and the Executive Chairman of Insys's Board of Directors—and that Insys Therapeutics Inc operated a scheme to promote the illegal and improper off-label marketing and sale of Subsys.

On January 25, 2016, another article was published entitled "The Brotherhood of Thieves: Insys Therapeutics," alleging that Insys Therapeutics' executives have continued to pressure Company employees to develop new schemes to promote the illegal and improper off-label marketing and sale of Subsys.

Those who purchased NASDAQ:INSY shares should contact the Shareholders Foundation, Inc. by e-mail at mail@shareholdersfoundation.com or call +1 (858) 779-1554.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

Primary Logo

 Top of page